Skip to main content
. 2021 Nov 4;186(1):R1–R14. doi: 10.1530/EJE-21-0794

Figure 4.

Figure 4

Effect of treatment with CRF1 receptor antagonists on CAH biomarkers. (A) Percentage fall in 17OHP and androstenedione (A4) after 14 days of Crinecerfont oral dosing: 50 mg at bedtime (n = 8), 100 mg at bedtime (n = 7), 100 mg once daily with an evening meal (n = 8), and 100 mg twice daily with meals (n = 8). (B) Percentage fall in 17OHP and A4 during Tildacerfont treatment in patients with poor control of CAH at baseline.